Celltrion presents data for biosimilar trastuzumab

Celltrion Inc. (KOSDAQ:068270) presented pooled data for CT-P6, a biosimilar version of cancer drug Herceptin trastuzumab, at the American Society of Clinical Oncology meeting. In 475 patients with confirmed HER2-positive metastatic breast cancer in a Phase I/IIb and III trial, CT-P6 plus paclitaxel was equivalent to Herceptin plus paclitaxel based on the primary endpoint of overall response rate (ORR) (57% vs. 62%). Additionally, Celltrion said both groups reported similar frequencies of serious adverse events and adverse events. The company could not be reached for next steps for CT-P6.

Celltrion and Hospira Inc. (NYSE:HSP) partnered in 2009 to develop and commercialize eight biosimilars in in the U.S., Europe, Australia, New Zealand and Canada. Nippon Kayaku Co. Ltd. (Tokyo:4272) is co-developing CT-P6 in Japan. Hospira was up $0.61 to $35.29 on Monday. ...